President, Gene Therapy, Catalent Biologics
Pete Buzy was named President, Gene Therapy in May 2019, when we acquired Paragon Bioservices. Prior to joining Catalent via the acquisition, Mr. Buzy had served as President & Chief Executive Officer of Paragon since 2016, having joined the company in 2014 as its Chief Operating Officer. With over 25 years of successful executive management experience, he grew Paragon into a premier CDMO with a leading position in gene therapy and next-generation vaccines.
Prior to that, Mr. Buzy spent over 13 years as a senior executive at Martek Biosciences Corporation, a leader in the innovation, development, production, and sale of high-value products from microbial sources that was publicly traded until being acquired. He played a key role in transforming Martek’s business from an R&D company to a fully integrated and profitable commercial organization with over $470 million in annual sales. Prior to his tenure at Martek, Mr. Buzy spent 13 years at Ernst & Young, where he advanced to Partner in the Northern Virginia High Technology and Life Science Practice, serving a variety of private and publicly traded biotechnology companies.
Mr. Buzy earned his BBA in accounting from Salisbury University in Maryland and serves on the Board and Executive Committees of the Technology Council of Maryland.